Giovanni Caforio, MD
Bristol-Myers Squibb and Nektar Therapeutics have announced plans to jointly develop and market combinations of the CD122-biased cytokine NKTR-214 with nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) for 20 indications in 9 tumor types. Under the terms of the agreement, Bristol-Myers Squibb will pay .85 billion to Nektar.
In preclinical research, NKTR-214 is being examined in combination with agents from Takeda Oncology. This collaboration, which was entered in May 2017, was focused on the exploration of NKTR-214 with 5 different Takeda compounds, including a SYK inhibitor and proteasome inhibitor, in tumor models for lymphoma, melanoma and colorectal cancer.
Diab A. Pivot-02: Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic melanoma, renal cell carcinoma and non-small cell lung cancer. Presented at: SITC 32nd Annual Meeting; National Harbor, MD; November 8-12, 2017. Session 207.7.
... to read the full story